Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature
Authors
Keywords
-
Journal
PEDIATRIC DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-07
DOI
10.1007/s40272-020-00396-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combination Biologic Therapy in Inflammatory Bowel Disease: Experience from a Tertiary Care Center
- (2020) Lukasz Kwapisz et al. Clinical Gastroenterology and Hepatology
- P084 DEEP REMISSION WITH DOUBLE BIOLOGIC THERAPY: A SUCCESSFUL CASE OF COMBINATION USTEKINUMAB AND VEDOLIZUMAB FOR SEVERE REFRACTORY CROHN'S DISEASE
- (2020) Ahmed Elmoursi et al. GASTROENTEROLOGY
- Characteristics of biological therapy in pediatric patients with Crohn’s disease
- (2019) Andras Tarnok et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials
- (2019) Shomron Ben-Horin et al. BMJ Open
- Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center
- (2019) Judy R. Dayan et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis
- (2019) Davide Giuseppe Ribaldone et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dermatological Manifestations in Pediatric Patients with Inflammatory Bowel Diseases on Anti-TNF Therapy
- (2018) Shilpa Sridhar et al. INFLAMMATORY BOWEL DISEASES
- Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series
- (2018) Lydia C T Buer et al. INFLAMMATORY BOWEL DISEASES
- Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review
- (2018) Francisco J. Melo et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease
- (2018) Anna-Maria Schneider et al. BMC GASTROENTEROLOGY
- Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease
- (2018) Karen van Hoeve et al. Journal of Crohns & Colitis
- Management of paediatric patients with medically-refractory Crohn’s disease using Ustekinumab: A multi-centred cohort study
- (2018) Mallory Chavannes et al. Journal of Crohns & Colitis
- Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohnʼs Disease
- (2017) Kayci Huff-Hardy et al. INFLAMMATORY BOWEL DISEASES
- Co-treatment With Golimumab and Vedolizumab to Treat Severe UC and Associated Spondyloarthropathy
- (2017) Xavier Roblin et al. Journal of Crohns & Colitis
- Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN
- (2017) Oren Ledder et al. Journal of Crohns & Colitis
- Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents
- (2017) Joshua B. Eickstaedt et al. PEDIATRIC DERMATOLOGY
- Ustekinumab and Anti-TNF Combination Therapy in Patients with Inflammatory Bowel Disease
- (2016) Clara Yzet et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- New treatments for ulcerative colitis: do we have pediatric data?
- (2016) Richard K. Russell et al. Expert Review of Clinical Immunology
- Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease
- (2016) Namita Singh et al. INFLAMMATORY BOWEL DISEASES
- Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease
- (2016) Máire A. Conrad et al. INFLAMMATORY BOWEL DISEASES
- An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
- (2016) Tim Wyant et al. Journal of Crohns & Colitis
- Ustekinumab in Pediatric Crohn Disease Patients
- (2016) Casey Bishop et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn’s Disease
- (2015) Robert Hirten et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study
- (2015) Ian Landells et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment
- (2013) Cornelia Tillack et al. GUT
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now